Tag: Biliary Tract Cancer

Durvalumab plus chemotherapy enhances 3-year survival in advanced biliary tract cancer

Presented By
Prof. Do-Youn Oh, Seoul National University, Korea
Trial
Phase 3, TOPAZ-1
Conference
ESMO GI 2024
Type
Peer-reviewed article

21 August 2024 11:53

SWOG 1815, first-ever phase 3 trial in BTC, fails

Presented By
Prof. Rachna Shroff, University of Arizona Cancer Center, AZ, USA
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 09:20

IMbrave 151 missed primary endpoint in advanced BTC

Presented By
Prof. Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, CA, USA
Trial
Phase 2, IMbrave151
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 09:15

Acceptable safety profile and encouraging efficacy of nanvuranlat in BTC

Presented By
Dr Junji Furuse, Kanagawa Cancer Center, Japan
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 09:11

Adjuvant S-1 therapy superior to observation in resected biliary tract cancer

Presented By
Dr Masafumi Ikeda, Japan Clinical Oncology Group, Japan
Trial
Phase 3, JCOG1202, ASCOT
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 10:13

TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer

Presented By
Dr Do-Youn Oh, Seoul National University College of Medicine, South Korea
Trial
Phase 3, TOPAZ-1
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 10:09

Zanidatamab provides ORR in HER2+ biliary tract cancer

Presented By
Prof. Funda Meric-Bernstam, University of Texas MD Anderson Cancer Center, USA
Trial
Phase 1
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:28
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com